Showing 3004 results
-
Press release /Regulus is a clinical-stage biopharmaceutical company developing microRNA therapeutics with a focus on autosomal dominant polycystic kidney disease (ADPKD), a severe renal diseaseLead asset for ADPKD…
-
Press release /Scemblix demonstrated sustained superior major molecular response (MMR) vs. all investigator-selected TKIs (74.1% vs. 52%) and vs. imatinib alone (76.2% vs. 47.1%), meeting both ASC4FIRST 96-week key…
-
Press release /In the Phase IIIB APPULSE-PNH study, oral Fabhalta® (iptacopan) improved the average hemoglobin (Hb) level versus baseline in adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who were…
-
Press release /Approval is based on Phase III NATALEE data showing Kisqali® (ribociclib) plus adjuvant endocrine therapy (ET) demonstrated clinically meaningful invasive disease-free survival (iDFS) benefit in…
-
Press release /Longer-term 96-week results from Scemblix® ASC4FIRST Phase III study in first-line Ph+ CML-CP to be presented following recent FDA approval based on 48-week data Late-breaking Kisqali®* 4-year…
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR Mid-term sales guidance upgraded to +6% CAGR 2023-2028 and +5% 2024-2029Strong momentum in the business with 8 in-market brands with USD 3bn+ to…
-
Event / May 12, 2025During Eurovision week, the Novartis Campus and the Novartis Pavillon will become a cultural hub, offering free public access, engaging experiences, and inspiring…
-
Event / Mar 31, 2025As Eurovision excitement builds, one of Basel’s most iconic forms of transport is getting a musical makeover. Starting March 31, 2025, the Eurovision tram has hit the…
-
Event / May 17, 2025On Saturday, May 17, 2025, as Basel hosts the Eurovision Song Contest, we invite you to Arena plus – an extraordinary public viewing event at St. Jakob-Park,…
-
Event / May 03, 2025As part of our Eurovision celebration in Basel, Feel the Beat invites people with and without hearing impairments to come together on one dance floor and experience…